摘要
目的探讨布地奈德对BA患者气管肺泡灌洗液（bronchoalveolar lavage fluid,BALF）中TGF-β_1表达影响。方法选择我科2010年2月~2014年2月住院AABA患者按就诊时间分为常规组和治疗组各45例。常规组予综合治疗,治疗组在此基础上予布地奈德吸入,疗程均为3周,对两组治疗前后BALF中TGF-β_1水平进行检测。结果常规组治疗前、治疗1周、治疗3周BALF中TGF-β_1浓度分别为（223.98±58.48）ng/L、（189.04±44.57）ng/L、（158.33±37.66）ng/L,治疗组治疗前、治疗1周、治疗3周BALF中TGF-β_1浓度分别为（231.60±61.11）ng/L、（170.31±32.19）ng/L、（135.20±17.94）ng/L;治疗1周后,治疗组与常规组差异有统计学意义（P〈0.05）,治疗3周后,治疗组与常规组比较,差异有高度统计学意义（P〈0.01）;BALF中TGF-β_1水平与BA分级呈正相关（r=0.938,P〈0.01）。结论 BALF中TGF-β_1能反映BA气道炎症情况,布地奈德能显著降低BALF中TGF-β_1水平。
Objective To observe the impaction of budesonide on the expression of TGF-β_1 in bronchoalveolar lavage of asthma. Methods The patients hospitalized in our department from February 2010 to February 2014 for the acute attack of asthma were selected and divided into the conventional group and the treatment group according to visiting time, with 45 cases each. The conventional group was treated with comprehensive therapy and the treatment group was treated with budesonide inhalation therapy on basis of the conventional group, and the course of treatment were 3weeks. The levels of TGF-β_1in BALF were measured before treatment and after treatment. Results The level of TGF-β_1before treatment, 1 week, 3 weeks of treatment were（223.98±58.48）ng/L,（189.04±44.57）ng/L,（158.33±37.66）ng/L in the conventional group respectively, and（231.60±61.11）ng/L,（170.31±32.19）ng/L,（135.20±17.94）ng/L in the treatment group respectively. There were significant differences between the treatment group and conventional group after 1week of treatment（P0.05） and the same after 3 weeks of treatment（P0.01）. And the concentration of TGF-β_1in BALF were positively correlated with classification of asthma（r=0.938, P0.01）. Conclusion The level of TGF-β_1can reflect airway inflammation of asthma, which can be significantly decrease by budesonide.
出处
《中国现代医生》
2016年第1期16-18,22,F0003,共5页
China Modern Doctor
基金
浙江省医药卫生一般研究计划(2015KYB446)
台州恩泽医疗中心(集团)科研基金项目(15EZA2)
浙江省第一批台州市科技计划项目(1301ky49)
